At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 273 enrolled
Drug / intervention
Etanercept +1 moredrug
Likely dose
Etanercept 50 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized, Double-Blind Trial Assessing the Efficacy and Safety of Etanercept 50 mg Twice Weekly and Etanercept 50 mg Once Weekly for the Treatment of Moderate to Severe Psoriasis
In Brief
A Phase 4 clinical trial evaluating Etanercept for Plaque Psoriasis and Psoriasis. Completed, enrolled 273 participants across 38 sites in 13 countries.
Detailed Summary
The purpose of this study is to compare the safety and efficacy of different doses of etanercept for the treatment of moderate to severe psoriasis.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPlaque Psoriasis, Psoriasis
CountriesArgentina, Austria, Belgium, Czechia, Germany, Greece, Hungary, Italy, Mexico, South Korea, Spain, Taiwan, Thailand
Collaborators--
Timeline
Phase 4CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedApr 2008
Enrollment StartJun 2008
Primary CompletionJan 2010
TodayJul 2026
First PostedApr 21, 2008
Enrollment StartJun 1, 2008
Primary CompletionJan 1, 2010
TodayJul 2, 2026
Enrollment to primary: 1.6 yearsPosted 18.2 years ago
Interventions
Etanerceptdrug
ETN 50 mg QW + PBO QW for 12 weeks followed by ETN 50 mg QW for 12 weeks.
Etanerceptdrug
ETN 50 mg BIW for 12 weeks folowed ETN 50 mg QW for 12 weeks.